SciSparc shares are trading higher after the company announced its subsidiary NeuroThera Labs received conditional TSX approval for the acquisition of approximately 54% of interest in CliniQuantum.

Benzinga Newsdesk www.benzinga.com Positive 94.5%

Neg 0% Neu 0% Pos 94.5%

Comments

No comments yet. Be the first!